RU2713333C2 - Способы получения т-клеток против антигена папилломавируса человека - Google Patents

Способы получения т-клеток против антигена папилломавируса человека Download PDF

Info

Publication number
RU2713333C2
RU2713333C2 RU2016103614A RU2016103614A RU2713333C2 RU 2713333 C2 RU2713333 C2 RU 2713333C2 RU 2016103614 A RU2016103614 A RU 2016103614A RU 2016103614 A RU2016103614 A RU 2016103614A RU 2713333 C2 RU2713333 C2 RU 2713333C2
Authority
RU
Russia
Prior art keywords
cells
hpv
patient
tumor
cancer
Prior art date
Application number
RU2016103614A
Other languages
English (en)
Russian (ru)
Other versions
RU2016103614A (ru
RU2016103614A3 (enExample
Inventor
Кристиан С. ХИНРИЧС
Стивен А. РОЗЕНБЕРГ
Original Assignee
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез filed Critical Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез
Publication of RU2016103614A publication Critical patent/RU2016103614A/ru
Publication of RU2016103614A3 publication Critical patent/RU2016103614A3/ru
Application granted granted Critical
Publication of RU2713333C2 publication Critical patent/RU2713333C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C12N7/025—Packaging cell lines, e.g. transcomplementing cell lines, for production of virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
RU2016103614A 2013-07-15 2014-07-14 Способы получения т-клеток против антигена папилломавируса человека RU2713333C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361846161P 2013-07-15 2013-07-15
US61/846,161 2013-07-15
PCT/US2014/046478 WO2015009604A1 (en) 2013-07-15 2014-07-14 Methods of preparing anti-human papillomavirus antigen t cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2019105050A Division RU2809610C2 (ru) 2013-07-15 2019-02-22 Способы получения т-клеток против антигена папилломавируса человека

Publications (3)

Publication Number Publication Date
RU2016103614A RU2016103614A (ru) 2017-08-16
RU2016103614A3 RU2016103614A3 (enExample) 2018-06-18
RU2713333C2 true RU2713333C2 (ru) 2020-02-04

Family

ID=51257632

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016103614A RU2713333C2 (ru) 2013-07-15 2014-07-14 Способы получения т-клеток против антигена папилломавируса человека

Country Status (9)

Country Link
US (8) US20160144018A1 (enExample)
EP (3) EP3626817B1 (enExample)
JP (2) JP6616295B2 (enExample)
CN (2) CN111733131A (enExample)
AU (4) AU2014290286A1 (enExample)
CA (1) CA2918080A1 (enExample)
ES (3) ES2932429T3 (enExample)
RU (1) RU2713333C2 (enExample)
WO (1) WO2015009604A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4223873A3 (en) 2015-01-31 2023-09-06 The Trustees of the University of Pennsylvania Compositions and methods for t cell delivery of therapeutic molecules
WO2017049237A1 (en) * 2015-09-18 2017-03-23 The General Hospital Corporation Dba Massachusetts General Hospital Personalized approach to dosage of anti-fugetactic agent for treatment of cancer
CN114231486A (zh) * 2015-10-30 2022-03-25 儿童国家医疗中心 从未致敏t细胞群体产生hpv抗原特异性t细胞
ES2964746T3 (es) * 2015-12-30 2024-04-09 Celgene Corp Métodos de producción de linfocitos T y linfocitos T producidos mediante el mismo
EP3519433A1 (en) 2016-10-03 2019-08-07 Juno Therapeutics, Inc. Hpv-specific binding molecules
PL3532607T3 (pl) 2016-10-26 2024-07-01 Iovance Biotherapeutics, Inc. Restymulacja kriokonserwowanych limfocytów naciekających guza nowotworowego
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
US20190350981A1 (en) * 2017-01-20 2019-11-21 Atara Biotherapeutics, Inc. Methods of treating multiple sclerosis using autologous t cells
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
AR112072A1 (es) 2017-06-05 2019-09-18 Iovance Biotherapeutics Inc Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
EP3692063A1 (en) 2017-10-03 2020-08-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
KR102956273B1 (ko) 2018-01-08 2026-04-24 이오반스 바이오테라퓨틱스, 인크. 종양 항원-특이적 t-세포에 대해 풍부화된 til 생성물의 생성 방법
EP3775238A1 (en) 2018-04-05 2021-02-17 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
CN112566698A (zh) 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞
AU2019247199A1 (en) 2018-04-05 2020-10-15 Editas Medicine, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
WO2019196088A1 (en) * 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
EP3784254A1 (en) 2018-04-27 2021-03-03 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
SG11202101204TA (en) 2018-08-09 2021-03-30 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
MX2021002574A (es) 2018-09-11 2021-06-08 Juno Therapeutics Inc Metodos para el analisis por espectrometria de masas de composiciones de celulas modificadas.
CR20210295A (es) 2018-11-05 2021-07-09 Iovance Biotherapeutics Inc Procesos para la producción de linfocitos infiltrantes de tumor y usos de estos en inmunoterapia
TW202039831A (zh) 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 對抗ｐｄ－１抗體呈現難治性之非小細胞肺癌（ｎｓｃｌｃ）病患之治療
GB201821207D0 (en) 2018-12-24 2019-02-06 Tcer Ab Immunotherapy therapy
AU2020265741A1 (en) 2019-05-01 2021-11-25 Editas Medicine, Inc. Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
KR20220119439A (ko) 2019-12-20 2022-08-29 인스틸 바이오 유케이 리미티드 종양 침윤 림프구를 분리하기 위한 장치 및 방법 및 그것의 용도
WO2021260186A1 (en) 2020-06-26 2021-12-30 Juno Therapeutics Gmbh Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
EP4225330A1 (en) 2020-10-06 2023-08-16 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022204564A2 (en) 2021-03-25 2022-09-29 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
WO2023196884A1 (en) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Detection assay for human papillomavirus (hpv) type 16 (hpv-16)
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2026090040A1 (en) * 2024-10-21 2026-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing cell therapy products for the treatment of conditions caused by human papillomavirus 6 or 11 infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110052530A1 (en) * 2009-08-28 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Adoptive cell therapy with young t cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
CN1609196A (zh) * 2003-10-17 2005-04-27 上海普泛生物科技有限公司 用于发现肿瘤特异性抗原和肿瘤特异性抗原决定簇的高产率t淋巴细胞克隆技术
WO2009102697A2 (en) * 2008-02-11 2009-08-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of obtaining antigen-specific t cell populations
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
CN102816734A (zh) * 2012-05-09 2012-12-12 阮润生 一种肿瘤抗原特异性t细胞的获取方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110052530A1 (en) * 2009-08-28 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Adoptive cell therapy with young t cells

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CRUZ C.R. et al. "Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience." Cytotherapy, 2010, 12(6): 743-749. *
CRUZ C.R. et al. "Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience." Cytotherapy, 2010, 12(6): 743-749. АКБЕРОВА Д.Р., БАТЫРШИНА С.В. "Папилломавирусная инфекция: современная диагностика и терапия." Практическая медицина, 2012, 9 (65):168-169. *
DUDLEY M.E. et al. "Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients." J Immunother., 2003, 26(4):332-42. *
EVANS E.M. et al. "Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes." Cancer Res., 1997, 57(14):2943-50. *
EVANS E.M. et al. "Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes." Cancer Res., 1997, 57(14):2943-50. HILDERS C.G.J.M. et al. "Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma." International journal of cancer, 1994, 57(6): 805-813. HEUSINKVELD M. et al. "Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer." International journal of cancer, 2012, 131(2):E74-E85. DUDLEY M.E. et al. "Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients." J Immunother., 2003, 26(4):332-42. *
HEUSINKVELD M. et al. "Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer." International journal of cancer, 2012, 131(2):E74-E85. *
HILDERS C.G.J.M. et al. "Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma." International journal of cancer, 1994, 57(6): 805-813. *
АКБЕРОВА Д.Р., БАТЫРШИНА С.В. "Папилломавирусная инфекция: современная диагностика и терапия." Практическая медицина, 2012, 9 (65):168-169. *

Also Published As

Publication number Publication date
AU2020233702A1 (en) 2020-10-08
AU2020233702B2 (en) 2023-06-29
RU2019105050A (ru) 2019-06-07
ES2932429T3 (es) 2023-01-19
EP3022294B1 (en) 2019-11-20
US11338032B2 (en) 2022-05-24
US20190117761A1 (en) 2019-04-25
US11918640B2 (en) 2024-03-05
US20210338796A1 (en) 2021-11-04
US20160144018A1 (en) 2016-05-26
AU2023233209B2 (en) 2025-10-16
ES3034357T3 (en) 2025-08-18
US20230139588A1 (en) 2023-05-04
CN105452448B (zh) 2020-07-28
CN105452448A (zh) 2016-03-30
AU2026200282A1 (en) 2026-02-05
AU2023233209A1 (en) 2023-10-12
US20210338795A1 (en) 2021-11-04
RU2016103614A (ru) 2017-08-16
CA2918080A1 (en) 2015-01-22
US20240382577A1 (en) 2024-11-21
EP4137564A1 (en) 2023-02-22
JP6616295B2 (ja) 2019-12-04
JP2016524914A (ja) 2016-08-22
US11376318B2 (en) 2022-07-05
US20210121559A1 (en) 2021-04-29
WO2015009604A1 (en) 2015-01-22
US11331385B2 (en) 2022-05-17
US20210338797A1 (en) 2021-11-04
EP4137564C0 (en) 2025-05-14
US11077182B2 (en) 2021-08-03
CN111733131A (zh) 2020-10-02
AU2014290286A1 (en) 2016-02-04
JP2020036601A (ja) 2020-03-12
ES2773548T3 (es) 2020-07-13
EP3626817B1 (en) 2022-09-28
EP3626817A1 (en) 2020-03-25
EP3022294A1 (en) 2016-05-25
RU2016103614A3 (enExample) 2018-06-18
JP7315435B2 (ja) 2023-07-26
EP4137564B1 (en) 2025-05-14

Similar Documents

Publication Publication Date Title
US11918640B2 (en) Methods of preparing anti-human papillomavirus antigen T cells
JP6257655B2 (ja) 末梢血から腫瘍反応性ｔ細胞の濃縮された集団を作製する方法
JP2018148898A (ja) 濃縮された腫瘍反応性ｔ細胞集団を腫瘍から作製する方法
US20210290672A1 (en) Regulation of tumor-associated t cells
RU2809610C2 (ru) Способы получения т-клеток против антигена папилломавируса человека
HK40088479B (en) Methods of preparing anti-human papillomavirus antigen t cells
HK40088479A (en) Methods of preparing anti-human papillomavirus antigen t cells
HK40038785A (en) Methods of preparing anti-human papillomavirus antigen t cells
HK40025869A (en) Methods of preparing anti-human papillomavirus antigen t cells
HK40025869B (en) Methods of preparing anti-human papillomavirus antigen t cells
O'Sullivan The role of the innate immune system in cancer immunoediting and rejection [electronic resource]